Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs

Sherard ES, Steinman GS, Couri D. Treatment of childhood epilepsy with valproic acid: results of the first 100 patients in a 6-month trial. Neurology 1980; 30: 31.

Dodson WE, Tasch V. Pharmacology of valproic acid in children with severe epilepsy: clearance and hepatotoxicity. Neurology 1981; 31: 1047.

Sato S, White BG, Penry JK. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 2: 157.

Dreifuss FE. Lennox-Gastaut syndrome. In: Dreifuss FE, ed. Pediatric Epileptology. Classification and management of seizures in the child. Boston: Wright; 1983: 126.

Porter RJ. Therapy: general considerations. In: Walton JN, ed. Major problems in neurology, vol 12. Epilepsy: 100 elementary principles. London: Saunders; 1984: 69.

Chayasirisobbon S, Russell M. Valproic acid and intractable seizures in severely brain-damaged patients. Neurology 1983; 33: 99.

Sills JA, Trefor-Jones RH, Taylor WH. Valproate, hyperammonemia and hyperglycinemia. Lancet 1980; II: 260.

Coulter DL, Allen RJ. Secondary hyperammonemia: a possible mechanism for valproate encephalopathy. Lancet 1980; I: 1310.

Warter JM, Marescaux C, Rumbach L, Galmiche J, Micheletti G, Koehl C, Imler M. L’hyperammoniémie isolée: une conséquence fréquente des traitements par la valproate de sodium. Nouv Presse Med 1981; 10: 3406.

Murphy JV, Marquardt K. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol 1982; 39: 591.

Zaret BS, Beckner RR, Marini AM, Wagle W, Passarelli C. Valproate-induced hyperammonemia without clinical hepatic dysfunction. Neurology 1982; 32: 206.

Wyllie E, Wyllie R, Rothner AD, Erenberg G, Cruse RP. Valproate-induced hyperammonemia in asymptomatic children. Cleve Clin Q 1983; 50: 275.

Williams CA, Tienfenbach S, Reynolds JW. Valproic acid-induced hyperammonemia in mentally retarded adults. Neurology 1984; 34: 550.

Zaccara G, Campostrini R, Paganini M, Messori A, Valenza T, Arnetoli G, Zappoli R. Acute changes of blood ammonia may predict short-term adverse effects of valproic acid. Neurology 1984; 34: 1519.

Marescaux C, Warter JM, Laroye M, Rumbach L, Micheletti G, Koehl C, Imler K, Kurtz D. Le valproate de sodium: une drogue hyperammoniémiante. Etude chez l’épileptique et chez le volontaire sain. J Neurol Sci 1983; 58: 195.

Zaccara G, Campostrini R, Paganini M, Messori A, Valenza T, Arnetoli G, Zappoli R. Long-term treatment with sodium valproate: monitoring of venous ammonia concentrations and adverse effects. Ther Drug Monit 1987; 9: 34.

Coulter DL, Allen RJ, Arbor A. Hyperammonemia with valproic acid therapy. J Pediatr 1981; 99: 317.

Warter JM, Marescaux C, Chabrier G, Rumbach L, Micheletti G, Reitzer B, Hirsch E, Imler M. Increase of valproate-induced hyperammonemia in normal subjects by carbohydrate intake. Neurology 1984; 34: 1487.

Sakemi K, Takada G. Effect of carnitine on valproic acid concentrations in serum, brain, and liver. Pediatr Neurol 1998; 18: 331.

Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 1982; 101: 782.

Chiarelli F, Verrotti A, Tumini S, Morgese G. Effects of normal carbohydrate/low fat diet on lipid metabolism in insulin-dependent diabetes mellitus in childhood. Diab Nutr Metab 1989; 2: 285.

Cederblad G, Linstedt S. A method for the determination of carnitine in the picomole range. Clin Chim Acta 1972; 37: 235.

McGarry JD, Foster DW. An improved and simplified radio isotopic assay for the determination of free and esterified carnitine. J Lipid Res 1976; 17: 277.

Geber N, Dickinson RG, Harland RC, Lynn RK, Houghton D, Antonias JI, Schimschock JC. Reye-like syndrome associated with valproic acid. J Pediatr 1979; 95: 142.

Young RSK, Bergman I, Gang DL, Richardson EP. Fetal Reyelike syndrome associated with valproic acid. Ann Neurol 1980; 7: 389.

Thom H, Carter PE, Cole GF, Stevenson KL. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev Med Child Neurol 1991; 33: 795.

Haidukewych D, John G, Zielinski JJ, Rodin EA. Chronic valproic acid therapy and incidence of increases in venous plasma ammonia. Ther Drug Monit 1985; 7: 290.

Ratnaike RN, Schapel GJ, Purdie G, Rischbieth RHC, Hoffmann S. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs. Br J Clin Pharmacol 1986; 22: 100.

Gago MC, Novo I, Segade SR. Effects of valproic acid on the urea cycle and carnitine metabolism. Int Pediatr 1990; 5: 54.

Warter JM, Marescaux C, Brandt C, Rumbach L, Micheletti G, Chabrier G, Imler M, Kurtz D. Sodium valproate associated with phenobarbital: effects on ammonia metabolism in humans. Epilepsia 1983; 24: 628.

Sakir A, Vildan B, Mehdi T, Özlem H, Refik B, Levent K. Asymptomatic hyperammonemia in children treated with valproic acid. J Child Neurol 1997; 12: 461.

Matsuda I, Ohtani Y, Ninomiya N. Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy. J Pediatr 1986; 109: 131.

Chapoy PR, Angelini C, Brown WJ, Stiff JE, Shug AL, Cederbaum SD. Systemic carnitine deficiency — a treatable inherited lipid-storage disease presenting as Reye’s syndrome. N Engl J Med 1980; 303: 1389.

Laub MC. Nutritional influence on serum ammonia in young patients receiving sodium valproate. Epilepsia 1986; 27: 55.

Warter JM, Imler M, Marescaux C, Chabrier G, Rumbach L, Micheletti G, Krieger J. Sodium valproate induced hyperammonemia in the rat: role of the kidney. Eur J Pharmacol 1983; 87: 177.

Jeavons PM. Non dose related side effects of valproate. Epilepsia 1984; 25 [Suppl I]: 850.

Zaccara G, Paganini M, Campostrini R, Messori A, Valenza T, Arnetoli G, Zappoli R. Effect of associated antiepileptic treatment in valproate-induced hyperammonemia. Ther Drug Monit 1985; 7: 185.